Holen Sie sich die Stockscreener-App
57.21
0.33%
0.19
Handel nachbörslich:
57.21
Schlusskurs vom Vortag:
$57.02
Offen:
$56.95
24-Stunden-Volumen:
736.84K
Relative Volume:
1.03
Marktkapitalisierung:
$4.09B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-18.45
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
-1.19%
1M Leistung:
+31.58%
6M Leistung:
+155.40%
1J Leistung:
+32.31%
1-Tages-Spanne:
$55.99
$57.75
1-Wochen-Bereich:
$55.99
$58.93
52-Wochen-Spanne:
$19.45
$59.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
57.21 | 4.08B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics Inc Stock Analysis and ForecastSupport and Resistance Levels & Free Stock Market Mentorship Programs - earlytimes.in
Full technical analysis of Kymera Therapeutics Inc. stock2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Kymera Therapeutics Inc. stock chart pattern explainedFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Ranking Kymera Therapeutics Inc. among high performing stocks via toolsWeekly Market Report & Risk Controlled Swing Alerts - newser.com
Should you hold or exit Kymera Therapeutics Inc. nowJuly 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Custom strategy builders for tracking Kymera Therapeutics Inc.2025 Earnings Surprises & Technical Pattern Recognition Alerts - newser.com
Top chart patterns to watch in Kymera Therapeutics Inc.Market Trend Review & Community Verified Watchlist Alerts - newser.com
Kymera Therapeutics Hits New 52-Week High of $59.00, Up 69% - Markets Mojo
Analyzing net buyer seller activity in Kymera Therapeutics Inc.Sell Signal & High Yield Stock Recommendations - newser.com
Will Kymera Therapeutics Inc. stock maintain momentum in 20252025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Tools to monitor Kymera Therapeutics Inc. recovery probabilityMarket Growth Summary & Capital Protection Trading Alerts - newser.com
Keudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics stock hits 52-week high at $58.97 By Investing.com - Investing.com Nigeria
Kymera Therapeutics stock hits 52-week high at $58.97 - Investing.com
What analysts say about Kymera Therapeutics Inc stockGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $59.95 - Defense World
Real time pattern detection on Kymera Therapeutics Inc. stockMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Given New $68.00 Price Target at Truist Financial - Defense World
Oppenheimer Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Hits New 52-Week High of $58.93, Up 65.21% - Markets Mojo
Is Codere Online Luxembourg SA a good long term investmentVolume Weighted Average Price & Learn the Basics of Investing in 5 Days - earlytimes.in
Oppenheimer Raises Price Target for Kymera Therapeutics (KYMR) t - GuruFocus
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline - Nasdaq
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $63 - 富途牛牛
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High Following Analyst Upgrade - Defense World
Truist Securities raises Kymera Therapeutics stock price target to $68 on KT-621 potential - Investing.com Canada
Truist Securities Boosts KYMR Price Target by Over 28% | KYMR Stock News - GuruFocus
Truist Financial Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00 - MarketBeat
Truist Raises Price Target on Kymera Therapeutics to $68 From $53, Keeps Buy Rating - MarketScreener
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $68 - 富途牛牛
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Published on: 2025-09-30 02:20:06 - newser.com
Kymera Therapeutics Hits New 52-Week High of $56.81, Up 64% Year-to-Date - Markets Mojo
Kymera Therapeutics (KYMR): Revisiting Valuation After Recent Share Price Momentum - Yahoo Finance
Kymera Therapeutics Gains Momentum with Price Target Upgrades - timothysykes.com
Is Kymera Therapeutics Inc a good long term investmentSector Performance Review & Affordable Portfolio Building - earlytimes.in
Kymera Therapeutics Price Target Boosted Amid Promising Clinical Data - timothysykes.com
Stocks To Watch: Kymera Therapeutics Sees RS Rating Jump To 83 - MSN
Kymera Therapeutics Hits New 52-Week High of $53.84, Reflecting Strong Growth - Markets Mojo
Kymera Therapeutics stock hits 52-week high at 53.31 USD By Investing.com - Investing.com Canada
Kymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month HighTime to Buy? - MarketBeat
Kymera Therapeutics stock hits 52-week high at 53.31 USD - Investing.com India
Certain Restricted Stock Units of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-SEP-2025. - MarketScreener
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kymera Therapeutics Inc-Aktie (KYMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobs Bruce N. | Chief Financial Officer |
Sep 17 '25 |
Sale |
50.00 |
79,220 |
3,961,380 |
227,409 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):